Literature DB >> 8075135

Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG).

D Flasher1, K Konopka, S M Chamow, P Dazin, A Ashkenazi, E Pretzer, N Düzgünes.   

Abstract

HIV-infected cells producing virions express the viral envelope glycoprotein gp120/gp41 on their surface. We examined whether liposomes coupled to recombinant soluble CD4 (sCD4, the ectodomain of CD4 which binds gp120 with high affinity) could specifically bind to HIV-infected cells. sCD4 was chemically coupled by 2 different methods to liposomes containing rhodamine-phosphatidylethanolamine in their membrane as a fluorescent marker. In one method, sCD4 was thiolated with N-succinimidyl acetylthioacetate (SATA) and coupled to liposomes via a maleimide-derivatised phospholipid. In the other method, the oligosaccharides on sCD4 were coupled to a sulfhydryl-derivatised phospholipid, utilizing the bifunctional reagent, 4-(4-N-maleimidophenyl)butyric acid hydrazide (MPBH). The association of the liposomes with HIV-1-infected or uninfected cells was examined by flow cytometry. CD4-coupled liposomes associated specifically to chronically infected H9/HTLV-IIIB cells, but not to uninfected H9 cells. CD4-coupled liposomes also associated specifically with monocytic THP-1 cells chronically infected with HIV-1 (THP-1/HIV-1IIIB). Control liposomes without coupled CD4 did not associate significantly with any of the cells, while free sCD4 could competitively inhibit the association of the CD4-coupled liposomes with the infected cells. The chimeric molecule CD4-immunoadhesin (CD4-IgG) could also be used as a ligand to target liposomes with covalently coupled Protein A (which binds the Fc region of the CD4-IgG) to H9/HTLV-IIIB cells. The CD4-liposomes inhibited the infectivity of HIV-1 in A3.01 cells, and also bound rgp120. Our results suggest that liposomes containing antiviral or cytotoxic agents may be targeted specifically to HIV-infected cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8075135     DOI: 10.1016/0005-2736(94)90219-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Progress in antiretroviral drug delivery using nanotechnology.

Authors:  Rama Mallipeddi; Lisa Cencia Rohan
Journal:  Int J Nanomedicine       Date:  2010-08-09

2.  Thermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes.

Authors:  Mikhail A Zhukovsky; Stéphane Basmaciogullari; Beatriz Pacheco; Liping Wang; Navid Madani; Hillel Haim; Joseph Sodroski
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

Review 3.  Nanotechnology and the treatment of HIV infection.

Authors:  Raveen Parboosing; Glenn E M Maguire; Patrick Govender; Hendrik G Kruger
Journal:  Viruses       Date:  2012-04-10       Impact factor: 5.048

Review 4.  Lipids and retroviruses.

Authors:  J Raulin
Journal:  Lipids       Date:  2000-02       Impact factor: 1.646

Review 5.  Targeting strategies for delivery of anti-HIV drugs.

Authors:  Lakshmi Narashimhan Ramana; Appakkudal R Anand; Swaminathan Sethuraman; Uma Maheswari Krishnan
Journal:  J Control Release       Date:  2014-08-10       Impact factor: 9.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.